The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
22
09
2021
accepted:
17
02
2022
revised:
07
02
2022
pubmed:
9
3
2022
medline:
15
7
2022
entrez:
8
3
2022
Statut:
ppublish
Résumé
To estimate the impact of oophorectomy and other treatments on the survival of breast cancer patients with a CHEK2 mutation. Women with Stage I-III breast cancer who were treated at 17 hospitals in Poland were tested for four founder mutations in the CHEK2 gene. 974 women (10%) were positive for a CHEK2 mutation. Control patients without a CHEK2 mutation were selected from a database of patients treated over the same time period. Information on treatments received and distant recurrences were retrieved from medical records. Treatments included chemotherapy, hormonal therapy (tamoxifen) and radiation therapy. Oophorectomies were performed for the treatment of breast cancer or for benign conditions. Dates of death were obtained from the Polish Vital Statistics Registry. Causes of death were determined by medical record review. Predictors of survival were determined using the Cox proportional hazards model. In all, 839 patients with a CHEK2 mutation were matched to 839 patients without a mutation. The mean follow-up was 12.0 years. The 15-year survival for CHEK2 carriers was 76.6% and the 15-year survival for non-carrier control patients was 78.8% (adjusted HR = 1.06; 95% CI: 0.84-1.34; P = 0.61). Among CHEK2 carriers, the 15-year survival for women who had an oophorectomy was 86.3% and for women who did not have an oophorectomy was 72.1% (adjusted HR = 0.59; 95% CI: 0.38-0.90; P = 0.02). Among controls, the 15-year survival for patients who had an oophorectomy was 84.5% and for women who did not have an oophorectomy was 77.6% (adjusted HR = 1.03; 95% CI: 0.66-1.61; P = 0.90). Among women with breast cancer and a CHEK2 mutation, oophorectomy is associated with a reduced risk of death from breast cancer.
Sections du résumé
BACKGROUND
To estimate the impact of oophorectomy and other treatments on the survival of breast cancer patients with a CHEK2 mutation.
METHODS
Women with Stage I-III breast cancer who were treated at 17 hospitals in Poland were tested for four founder mutations in the CHEK2 gene. 974 women (10%) were positive for a CHEK2 mutation. Control patients without a CHEK2 mutation were selected from a database of patients treated over the same time period. Information on treatments received and distant recurrences were retrieved from medical records. Treatments included chemotherapy, hormonal therapy (tamoxifen) and radiation therapy. Oophorectomies were performed for the treatment of breast cancer or for benign conditions. Dates of death were obtained from the Polish Vital Statistics Registry. Causes of death were determined by medical record review. Predictors of survival were determined using the Cox proportional hazards model.
RESULTS
In all, 839 patients with a CHEK2 mutation were matched to 839 patients without a mutation. The mean follow-up was 12.0 years. The 15-year survival for CHEK2 carriers was 76.6% and the 15-year survival for non-carrier control patients was 78.8% (adjusted HR = 1.06; 95% CI: 0.84-1.34; P = 0.61). Among CHEK2 carriers, the 15-year survival for women who had an oophorectomy was 86.3% and for women who did not have an oophorectomy was 72.1% (adjusted HR = 0.59; 95% CI: 0.38-0.90; P = 0.02). Among controls, the 15-year survival for patients who had an oophorectomy was 84.5% and for women who did not have an oophorectomy was 77.6% (adjusted HR = 1.03; 95% CI: 0.66-1.61; P = 0.90).
CONCLUSION
Among women with breast cancer and a CHEK2 mutation, oophorectomy is associated with a reduced risk of death from breast cancer.
Identifiants
pubmed: 35256754
doi: 10.1038/s41416-022-01770-1
pii: 10.1038/s41416-022-01770-1
pmc: PMC9276789
doi:
Substances chimiques
Checkpoint Kinase 2
EC 2.7.1.11
CHEK2 protein, human
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
84-91Investigateurs
M Błasińska-Morawiec
(M)
M Chosia
(M)
K Drosik
(K)
S Gozdecka-Grodecka
(S)
S Goźdź
(S)
E Grzybowska
(E)
A Jeziorski
(A)
A Karczewska
(A)
R Kordek
(R)
A Synowiec
(A)
B Kozak-Klonowska
(B)
K Lamperska
(K)
D Lange
(D)
A Mackiewicz
(A)
J Mituś
(J)
S Niepsuj
(S)
O Oszurek
(O)
K Gugala
(K)
Z Morawiec
(Z)
T Mierzwa
(T)
M Posmyk
(M)
J Ryś
(J)
C Szczylik
(C)
M Uciński
(M)
K Urbański
(K)
B Waśko
(B)
P Wandzel
(P)
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Cybulski C, Kluźniak W, Huzarski T, Wokołorczyk D, Kashyap A, Jakubowska A, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol. 2015;16:638–44.
doi: 10.1016/S1470-2045(15)70142-7
Jonasson JG, Stefansson OA, Johannsson OT, Sigurdsson H, Agnarsson BA, Olafsdottir GH, et al. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. Br J Cancer. 2016;115:776–83.
doi: 10.1038/bjc.2016.249
Olafsdottir EJ, Borg A, Jensen MB, Gerdes AM, Johansson ALV, Barkardottir RB, et al. Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status. Br J Cancer. 2020;123:1608–15.
doi: 10.1038/s41416-020-01056-4
Evans DG, Phillips KA, Milne R, Fruscio R, Cybulski C, Gronwald J, et al. Survival from breast cancer in women with a BRCA2 mutation by treatment. Br J Cancer. 2021;124:1524–32.
doi: 10.1038/s41416-020-01164-1
Narod SA, Huzarski T, Gronwald J, Byrski T, Marczyk E, Cybulski C, et al. Predictors of survival for breast cancer patients with a BRCA1 mutation. Breast Cancer Res Treat. 2018;168:513–21.
doi: 10.1007/s10549-017-4605-x
Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol. 2015;1:306–13.
doi: 10.1001/jamaoncol.2015.0658
Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018;24:628–37.
doi: 10.1038/s41591-018-0009-7
Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011;29:3739–46.
doi: 10.1200/JCO.2011.35.2682
Gordhandas S, Norquist BM, Pennington KP, Yung RL, Laya MB, Swisher EM. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. Gynecol Oncol. 2019;153:192–200.
doi: 10.1016/j.ygyno.2018.12.014
Holmberg L, Anderson H. HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363:453–5.
doi: 10.1016/S0140-6736(04)15493-7
Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet. 2002;31:55–59.
Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, et al. A population-based study of genes previously implicated in breast cancer. N. Engl J Med. 2021;384:440–51.
doi: 10.1056/NEJMoa2005936
Breast Cancer Association Consortium, Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C, et al. Breast cancer risk genes - association analysis in more than 113,000 women. N. Engl J Med. 2021;384:428–39.
doi: 10.1056/NEJMoa1913948
Narod SA. Which genes for hereditary breast cancer? N. Engl J Med. 2021;384:471–3.
doi: 10.1056/NEJMe2035083
Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science. 1998;282:1893–7.
doi: 10.1126/science.282.5395.1893
Cybulski C, Wokołorczyk D, Jakubowska A, Huzarski T, Byrski T, Gronwald J, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol. 2011;29:3747–52.
doi: 10.1200/JCO.2010.34.0778
Cybulski C, Wokołorczyk D, Huzarski T, Byrski T, Gronwald J, Górski B, et al. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. Breast Cancer Res Treat. 2007;102:119–22.
doi: 10.1007/s10549-006-9320-y
Cybulski C, Huzarski T, Byrski T, Gronwald J, Debniak T, Jakubowska A, et al. Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention. Clin Genet. 2009;75:72–8.
doi: 10.1111/j.1399-0004.2008.01111.x
Cybulski C, Kluźniak W, Huzarski T, Wokołorczyk D, Kashyap A, Rusak B, et al. The spectrum of mutations predisposing to familial breast cancer in Poland. Int J Cancer. 2019;145:3311–20.
doi: 10.1002/ijc.32492
Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analysis of 26,000 patient cases and 27,000 controls. J Clin Oncol. 2008;26:542–8.
doi: 10.1200/JCO.2007.12.5922
Weischer M, Nordestgaard BG, Pharoah P, Bolla MK, Nevanlinna H, Van’t Veer LJ, et al. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol. 2012;30:4308–16.
doi: 10.1200/JCO.2012.42.7336
Muranen TA, Blomqvist C, Dörk T, Jakubowska A, Heikkilä P, Fagerholm R, et al. Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium. Breast Cancer Res. 2016;18:98.
doi: 10.1186/s13058-016-0758-5
Kriege M, Hollestelle A, Jager A, Huijts PE, Berns EM, Sieuwerts AM, et al. Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy. Br J Cancer. 2014;111:1004–13.
doi: 10.1038/bjc.2014.306
Greville-Heygate SL, Maishman T, Tapper WJ, Cutress RI, Copson E, Dunning AM, et al. Pathogenic variants in CHEK2 are associated with an adverse prognosis in symptomatic early-onset breast cancer. JCO Precis Oncol. 2020;4:PO.19.00178.
pubmed: 32923877
pmcid: 7446368
Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT, et al. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol. 2007;25:64–69.
doi: 10.1200/JCO.2006.06.3024
Pfeifer W, Sokolenko AP, Potapova ON, Bessonov AA, Ivantsov AO, Laptiev SA, et al. Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers. Breast Cancer Res Treat. 2014;148:675–83.
doi: 10.1007/s10549-014-3206-1
Liu Y, Xu Y, Ouyang T, Li J, Wang T, Fan Z, et al. Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer. BMC Cancer. 2015;15:194.
doi: 10.1186/s12885-015-1203-3
Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, et al. TBCRC 048: phase II study of Olaparib for metastatic breast cancer and mutations in homologous recombination-related Genes. J Clin Oncol. 2020;38:4274–82.
doi: 10.1200/JCO.20.02151
Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, et al. Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Res. 2012;14:R47.
doi: 10.1186/bcr3147
Huzarski T, Cybulski C, Wokolorczyk D, Jakubowska A, Byrski T, Gronwald J, et al. Survival from breast cancer in patients with CHEK2 mutations. Breast Cancer Res Treat. 2014;144:397–403.
doi: 10.1007/s10549-014-2865-2